Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms

Rory R. Goodwin, Nancy Abu-Bonsrah, Laurence D. Rhines, Jorrit Jan Verlaan, Mark Bilsky, Ilya Laufer, Stefano Boriani, Daniel M. Sciubba, Chetan Bettegowda

Research output: Contribution to journalArticle

Abstract

STUDY TYPE.: Review of the Literature OBJECTIVE.: To discuss the evolution of molecular signatures and the history and development of targeted therapeutics in metastatic tumor types affecting the spinal column. SUMMARY OF BACKGROUND DATA.: Molecular characterization of metastatic spine tumors is expected to usher in a revolution in diagnostic and treatment paradigms. Molecular characterization will provide critical information that can be used for initial diagnosis, prognosticating the ideal treatment strategy, assessment of treatment efficacy, surveillance and monitoring recurrence, and predicting complications, clinical outcome, and overall survival in patients diagnosed with metastatic cancers to the spinal column. METHODS.: A review of the literature was performed focusing on illustrative examples of the role that molecular based therapeutics have played in clinical outcomes for patients diagnosed with metastatic tumor types affecting the spinal column. RESULTS.: The impact of molecular therapeutics including receptor tyrosine kinases and immune checkpoint inhibitors and the ability of molecular signatures to provide prognostic information are discussed in metastatic breast cancer, lung cancer, prostate cancer, melanoma, and renal cell cancer affecting the spinal column. CONCLUSION.: For the providers who will ultimately counsel patients diagnosed with metastases to the spinal column, molecular advancements will radically alter the management/surgical paradigms utilized. Ultimately, the translation of these molecular advancements into routine clinical care will greatly improve the quality and quantity of life for patients diagnosed with spinal malignancies and provide better overall outcomes and counseling for treating physicians.Level of Evidence: N/A

Original languageEnglish
Pages (from-to)S218-S223
Number of pages6
JournalSpine
DOIs
Publication statusAccepted/In press - Aug 3 2016

Fingerprint

Spine
Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Therapeutics
Aptitude
Molecular Evolution
Receptor Protein-Tyrosine Kinases
Renal Cell Carcinoma
Counseling
Melanoma
History
Quality of Life
Breast Neoplasms
Neoplasm Metastasis
Physicians
Recurrence
Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Orthopedics and Sports Medicine

Cite this

Goodwin, R. R., Abu-Bonsrah, N., Rhines, L. D., Verlaan, J. J., Bilsky, M., Laufer, I., ... Bettegowda, C. (Accepted/In press). Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms. Spine, S218-S223. https://doi.org/10.1097/BRS.0000000000001833

Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine : Changing the Treatment Paradigms. / Goodwin, Rory R.; Abu-Bonsrah, Nancy; Rhines, Laurence D.; Verlaan, Jorrit Jan; Bilsky, Mark; Laufer, Ilya; Boriani, Stefano; Sciubba, Daniel M.; Bettegowda, Chetan.

In: Spine, 03.08.2016, p. S218-S223.

Research output: Contribution to journalArticle

Goodwin, RR, Abu-Bonsrah, N, Rhines, LD, Verlaan, JJ, Bilsky, M, Laufer, I, Boriani, S, Sciubba, DM & Bettegowda, C 2016, 'Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms', Spine, pp. S218-S223. https://doi.org/10.1097/BRS.0000000000001833
Goodwin, Rory R. ; Abu-Bonsrah, Nancy ; Rhines, Laurence D. ; Verlaan, Jorrit Jan ; Bilsky, Mark ; Laufer, Ilya ; Boriani, Stefano ; Sciubba, Daniel M. ; Bettegowda, Chetan. / Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine : Changing the Treatment Paradigms. In: Spine. 2016 ; pp. S218-S223.
@article{adcacb2a2e794252aec97c10d1925d9b,
title = "Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms",
abstract = "STUDY TYPE.: Review of the Literature OBJECTIVE.: To discuss the evolution of molecular signatures and the history and development of targeted therapeutics in metastatic tumor types affecting the spinal column. SUMMARY OF BACKGROUND DATA.: Molecular characterization of metastatic spine tumors is expected to usher in a revolution in diagnostic and treatment paradigms. Molecular characterization will provide critical information that can be used for initial diagnosis, prognosticating the ideal treatment strategy, assessment of treatment efficacy, surveillance and monitoring recurrence, and predicting complications, clinical outcome, and overall survival in patients diagnosed with metastatic cancers to the spinal column. METHODS.: A review of the literature was performed focusing on illustrative examples of the role that molecular based therapeutics have played in clinical outcomes for patients diagnosed with metastatic tumor types affecting the spinal column. RESULTS.: The impact of molecular therapeutics including receptor tyrosine kinases and immune checkpoint inhibitors and the ability of molecular signatures to provide prognostic information are discussed in metastatic breast cancer, lung cancer, prostate cancer, melanoma, and renal cell cancer affecting the spinal column. CONCLUSION.: For the providers who will ultimately counsel patients diagnosed with metastases to the spinal column, molecular advancements will radically alter the management/surgical paradigms utilized. Ultimately, the translation of these molecular advancements into routine clinical care will greatly improve the quality and quantity of life for patients diagnosed with spinal malignancies and provide better overall outcomes and counseling for treating physicians.Level of Evidence: N/A",
author = "Goodwin, {Rory R.} and Nancy Abu-Bonsrah and Rhines, {Laurence D.} and Verlaan, {Jorrit Jan} and Mark Bilsky and Ilya Laufer and Stefano Boriani and Sciubba, {Daniel M.} and Chetan Bettegowda",
year = "2016",
month = "8",
day = "3",
doi = "10.1097/BRS.0000000000001833",
language = "English",
pages = "S218--S223",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine

T2 - Changing the Treatment Paradigms

AU - Goodwin, Rory R.

AU - Abu-Bonsrah, Nancy

AU - Rhines, Laurence D.

AU - Verlaan, Jorrit Jan

AU - Bilsky, Mark

AU - Laufer, Ilya

AU - Boriani, Stefano

AU - Sciubba, Daniel M.

AU - Bettegowda, Chetan

PY - 2016/8/3

Y1 - 2016/8/3

N2 - STUDY TYPE.: Review of the Literature OBJECTIVE.: To discuss the evolution of molecular signatures and the history and development of targeted therapeutics in metastatic tumor types affecting the spinal column. SUMMARY OF BACKGROUND DATA.: Molecular characterization of metastatic spine tumors is expected to usher in a revolution in diagnostic and treatment paradigms. Molecular characterization will provide critical information that can be used for initial diagnosis, prognosticating the ideal treatment strategy, assessment of treatment efficacy, surveillance and monitoring recurrence, and predicting complications, clinical outcome, and overall survival in patients diagnosed with metastatic cancers to the spinal column. METHODS.: A review of the literature was performed focusing on illustrative examples of the role that molecular based therapeutics have played in clinical outcomes for patients diagnosed with metastatic tumor types affecting the spinal column. RESULTS.: The impact of molecular therapeutics including receptor tyrosine kinases and immune checkpoint inhibitors and the ability of molecular signatures to provide prognostic information are discussed in metastatic breast cancer, lung cancer, prostate cancer, melanoma, and renal cell cancer affecting the spinal column. CONCLUSION.: For the providers who will ultimately counsel patients diagnosed with metastases to the spinal column, molecular advancements will radically alter the management/surgical paradigms utilized. Ultimately, the translation of these molecular advancements into routine clinical care will greatly improve the quality and quantity of life for patients diagnosed with spinal malignancies and provide better overall outcomes and counseling for treating physicians.Level of Evidence: N/A

AB - STUDY TYPE.: Review of the Literature OBJECTIVE.: To discuss the evolution of molecular signatures and the history and development of targeted therapeutics in metastatic tumor types affecting the spinal column. SUMMARY OF BACKGROUND DATA.: Molecular characterization of metastatic spine tumors is expected to usher in a revolution in diagnostic and treatment paradigms. Molecular characterization will provide critical information that can be used for initial diagnosis, prognosticating the ideal treatment strategy, assessment of treatment efficacy, surveillance and monitoring recurrence, and predicting complications, clinical outcome, and overall survival in patients diagnosed with metastatic cancers to the spinal column. METHODS.: A review of the literature was performed focusing on illustrative examples of the role that molecular based therapeutics have played in clinical outcomes for patients diagnosed with metastatic tumor types affecting the spinal column. RESULTS.: The impact of molecular therapeutics including receptor tyrosine kinases and immune checkpoint inhibitors and the ability of molecular signatures to provide prognostic information are discussed in metastatic breast cancer, lung cancer, prostate cancer, melanoma, and renal cell cancer affecting the spinal column. CONCLUSION.: For the providers who will ultimately counsel patients diagnosed with metastases to the spinal column, molecular advancements will radically alter the management/surgical paradigms utilized. Ultimately, the translation of these molecular advancements into routine clinical care will greatly improve the quality and quantity of life for patients diagnosed with spinal malignancies and provide better overall outcomes and counseling for treating physicians.Level of Evidence: N/A

UR - http://www.scopus.com/inward/record.url?scp=84980373347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980373347&partnerID=8YFLogxK

U2 - 10.1097/BRS.0000000000001833

DO - 10.1097/BRS.0000000000001833

M3 - Article

AN - SCOPUS:84980373347

SP - S218-S223

JO - Spine

JF - Spine

SN - 0362-2436

ER -